Evidence map›Paper›PMID 24629025›Full record

ArticleBMC cancer2014

Imagine a world without cancer.

Björn L D M Brücher, Gary Lyman, Richard van Hillegersberg, Raphael E Pollock, Florian Lordick, Han-Kwang Yang, Toshikazu Ushijima, Khay-Guan Yeoh, Tomas Skricka, Wojciech Polkowski and 16 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Breast Cancer CAFs: Spectrum of Phenotypes and Promising Targeting Avenues.International journal of molecular sciences · 2021
    Review
  5. Phenotypic Plasticity of Fibroblasts during Mammary Carcinoma Development.International journal of molecular sciences · 2019
    Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 20 institutions in 12 countries.

Björn L D M BrücherTheodor-Billroth-Academy®, Munich, Germany. b-bruecher@gmx.de.
Gary Lyman
Richard van Hillegersberg
Raphael E Pollock
Florian Lordick
Han-Kwang Yang
Toshikazu Ushijima
Khay-Guan Yeoh
Tomas Skricka
Wojciech Polkowski
Grzegorz Wallner
Vic Verwaal
Alfredo Garofalo
Domenico D'Ugo
Franco Roviello
Hans-Ulrich Steinau
Timothy J Wallace
Martin Daumer
Nitah Maihle
Thomas J Reid
Michel Ducreux
Yuko Kitagawa
Alexander Knuth
Bruno Zilberstein
Scott R Steele
Ijaz S Jamall
Medical University of Lublin · PLAugusta University · USClinical Research Consortium · USHealth Decisions (United States) · USInstitut Gustave Roussy · FRInstituto Nazionale Tumori Regina ElenaKeio University · JPMadigan Army Medical Center · USMasaryk University · CZNational Center for Cancer Care and Research · QANational University of Singapore · SGRegional Cancer Center · USSeoul National University Hospital · KRThe Netherlands Cancer Institute · NLThe Ohio State University · USUniversidade de São Paulo · BRUniversità Cattolica del Sacro Cuore · ITUniversity Medical Center Utrecht · NLUniversity of Siena · ITUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSince the "War on Cancer" was declared in 1971, the United States alone has expended some $300 billion on research, with a heavy focus on the role of genomics in anticancer therapy. Voluminous data have been collected and analyzed. However, in hindsight, any achievements made have not been realized in clinical practice in terms of overall survival or quality of life extended. This might be justified because cancer is not one disease but a conglomeration of multiple diseases, with widespread heterogeneity even within a single tumor type. DISCUSSION: Only a few types of cancer have been described that are associated with one major signaling pathway. This enabled the initial successful deployment of targeted therapy for such cancers. However, soon after this targeted approach was initiated, it was subverted as cancer cells learned and reacted to the initial treatments, oftentimes rendering the treatment less effective or even completely ineffective. During the past 30 plus years, the cancer classification used had, as its primary aim, the facilitation of communication and the exchange of information amongst those caring for cancer patients with the end goal of establishing a standardized approach for the diagnosis and treatment of cancers. This approach should be modified based on the recent research to affect a change from a service-based to an outcome-based approach. The vision of achieving long-term control and/or eradicating or curing cancer is far from being realized, but not impossible. In order to meet the challenges in getting there, any newly proposed anticancer strategy must integrate a personalized treatment outcome approach. This concept is predicated on tumor- and patient-associated variables, combined with an individualized response assessment strategy for therapy modification as suggested by the patient's own results. As combined strategies may be outcome-orientated and integrate tumor-, patient- as well as cancer-preventive variables, this approach is likely to result in an optimized anticancer strategy. SUMMARY: Herein, we introduce such an anticancer strategy for all cancer patients, experts, and organizations: Imagine a World without Cancer.

Indexed as

Early Detection of CancerPrecision MedicineAntineoplastic ProtocolsCombined Modality TherapyHumansNeoplasms

Identifiers

PMID24629025
PMCPMC3995593
OpenAlexW2138189757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.